Lintuzumab

The company said in a news release Monday morning that it would discontinue development of the drug, called lintuzumab, which could have been its first product to reach the market. ❋ Unknown (2010)

Unlike lintuzumab, which is an older "naked" antibody, SGN35 is a conjugate made up of a tumor-targeting antibody linked to a chemotherapy drug called monomethyl auristatin E. ❋ Unknown (2010)

The company said in a press release Monday morning that it would discontinue development of the drug, called lintuzumab, which might have been its first product to reach the market. ❋ Unknown (2010)

The Bothell, Wash., biotechnology company said it will end development of its experimental leukemia drug lintuzumab after a mid-stage trial of the treatment on older patients didn't meet its primary endpoint of extending overall survival. ❋ Unknown (2010)

Operating expenses will be primarily directed towards brentuximab vedotin pivotal development and pre-commercialization activities, as well as development and clinical activities for lintuzumab, SGN-75 and ASG-5ME. ❋ Unknown (2010)

Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab ❋ Unknown (2010)

Continued patient treatment and follow-up in a randomized phase IIb trial of lintuzumab plus low-dose chemotherapy for patients 60 years and older with acute myeloid leukemia to determine if the combination extends overall survival; data from this trial are expected in the second quarter of ❋ Unknown (2010)

We also expect to report key data from a second late-stage program, lintuzumab, in the second quarter of 2010. ❋ Unknown (2010)

While the focus may be on SGN-35, a surprise may lie in store with its other advanced candidate, the naked antibody SGN-33 (lintuzumab). ❋ Unknown (2010)

In addition, Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75. ❋ Unknown (2010)

Fourth quarter 2009 expenses decreased compared to the fourth quarter of 2008 as a result of lower manufacturing costs for dacetuzumab and brentuximab vedotin, and decreased lintuzumab clinical trial costs. ❋ Unknown (2010)